A new study published in Communications Biology suggests that psilocybin, the psychoactive compound found in magic mushrooms, may help protect the brain from damage caused by repeated mild head impacts. While current treatments for such injuries are limited to observation and rest, early results indicate the psychedelic could repair neural damage and potentially ward off future neurodegenerative disorders.
Although the research was conducted on laboratory rats, the findings highlight a possible gap in head trauma care. Mild head impacts, while not serious enough to cause concussions or loss of consciousness, have been linked to cumulative long-term effects. Over time, these injuries can increase the risk of dementia and conditions like chronic traumatic encephalopathy (CTE).
Argel Aguilar-Valles, an associate professor of neuroscience at Carleton University in Ontario and co-author of the study, explained that the research focused on the cumulative impact of minor hits common in children and older adults. The team induced three controlled mild head injuries in rats, which resulted in measurable alterations in brain structure and activity via MRI and functional MRI scans.
“There is no intervention — for instance, if we do this treatment, it’s going to prevent you from developing dementia 50 years down the line. There’s obviously nothing like that,” said Aguilar-Valles, noting that medical professionals typically advise parents to monitor children with mild head bumps and apply ice, without offering preventative pharmacological options.
The study utilized a dose of 3 milligrams per kilogram of body weight, a level significant enough to potentially induce hallucinogenic effects in rodents, as indicated by the “head twitch response.” Researchers observed notable recovery nearly three weeks post-injury. Psilocybin treatment reversed increased phosphorylation of tau, a protein associated with Alzheimer’s disease, and dramatically improved functional brain connectivity. Interestingly, treated rats exhibited hyperconnectivity that exceeded levels seen in uninjured control animals.
Aguilar-Valles attributed the therapeutic potential to the class of drugs known as psychoplastogens, which include psilocybin, LSD, ketamine, and MDMA. These substances promote brain plasticity by increasing dendritic complexity and synaptic spine density. While the exact mechanisms in physical trauma differ from those in psychiatric conditions like depression, the drugs appear to target common plasticity pathways.
The focus on psilocybin over other psychedelics, such as LSD, is partly logistical. Psilocybin’s effects last only a few hours, whereas LSD trips can extend much longer, requiring extended clinical supervision. This shorter duration makes psilocybin a more practical candidate for future clinical trials.
The researchers also found significant effects in dopaminergic nuclei, regions crucial for overall brain function, suggesting the drug may modulate widespread neural networks. However, Aguilar-Valles cautioned that it is not yet known whether the intensity of the psychedelic experience correlates with therapeutic benefit, a topic currently under active debate. The study remains preclinical, and further research is needed to determine if these results can be translated to human patients.
Leave a Reply